The European Commission unveiled this week one of its most significant health proposals, the Critical Medicines Act, which aims to enhance the security of supply and availability of essential medicines across the EU.
While ambitious in some areas, such as a proposed "Buy European" mechanism and new class of 'common interest' medicines, in other respects it was unspectacular, particularly in coordinating contingency stock. Funding, as so often on health matters, remains a key concern.
